Preferred Label : zokinvy;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3424350/fr/zokinvy-lonafarnib-maladie-rare
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
adolescent
progeria
orphan drug production
progeria
Laminopathies
Laminopathies
genetic testing
Product containing only lonafarnib in oral dose form (medicinal product form)
evaluation of the transparency committee
zokinvy
rare diseases
lonafarnib

---
https://www.has-sante.fr/jcms/p_3455546/fr/zokinvy-lonafarnib-syndrome-de-hutchinson-gilford
2023
false
false
false
France
French
treatment outcome
insurance, health, reimbursement
progeria
lonafarnib
lonafarnib
evaluation of the transparency committee
zokinvy
Laminopathies
administration, oral

---
https://www.has-sante.fr/jcms/p_3368156/fr/zokinvy-lonafarnib-syndrome-de-hutchinson-gilford
2022
false
false
false
France
progeria
treatment outcome
insurance, health, reimbursement
infant
child
Laminopathies
Laminopathies
mutation
LMNA Gene
zinc metallopeptidase STE24
guidelines for drug use
administration, oral
continuity of patient care
evaluation of the transparency committee
zokinvy
lonafarnib

---
Nous contacter.
18/06/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.